The current state of vaccine development for ocular HSV-1 infection

Expert Review of Ophthalmology

Volumn 10, Issue 2, 2015, Pages 113-126

  Royer, Derek J ^a   Cohen, Alex W ^a   Carr, Daniel J J ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

cornea; correlates of protection; HSV 1; immunopathology; vaccine

Indexed keywords

HERPES SIMPLEX VACCINE; HERPES SIMPLEX VIRUS 1 VACCINE; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE;

DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFICACY; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES ZOSTER; HUMAN; INCIDENCE; MEDICAL RESEARCH; NONHUMAN; OPHTHALMOLOGIST; REVIEW; SEROPREVALENCE; VACCINATION; VACCINE PRODUCTION; VIROLOGY; VIRUS REACTIVATION;

EID: 84925650037     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2015.1004315     Document Type: Review

References (122)

1. Halford WP. Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines? Expert Rev Vaccines 2014;13(6):691-710
2. Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol 2012;57(5):448-62
3. Divito SJ, Hendricks RL. Activated inflammatory infiltrate in HSV-1-infected corneas without herpes stromal keratitis. Invest Ophthalmol Vis Sci 2008;49(4): 1488-95
4. Yun H, Rowe AM, Lathrop KL, et al. Reversible nerve damage and corneal pathology in murine herpes simplex stromal keratitis. J Virol 2014;88(14):7870-80
5. Hamrah P, Cruzat A, Dastjerdi MH, et al. Corneal sensation and subbasal nerve alterations in patients with herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology 2010;117(10):1930-6
6. Gallar J, Tervo TMT, Neira W, et al. Selective changes in human corneal sensation associated with herpes simplex virus keratitis. Invest Ophthalmol Vis Sci 2010;51(9):4516-22
7. Mott KR, Bresee CJ, Allen SJ, et al. Level of herpes simplex virus type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice. J Virol 2009;83(5):2246-54
8. Al-Dujaili LJ, Clerkin PP, Clement C, et al. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol 2011; 6(8):877-907
9. Chentoufi AA, Kritzer E, Yu DM, et al. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin Dev Immunol 2012;2012:187585
10. Arvin AM. editor. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press; Cambridge, New York 2007
11. Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J Gen Virol 1986;67(Pt 9):1759-816
12. Macdonald SJ, Mostafa HH, Morrison LA, Davido DJ. Genome sequence of herpes simplex virus 1 strain KOS. J Virol 2012; 86(11):6371-2
13. Halford WP, Weisend C, Grace J, et al. ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol J 2006;3:44
14. Campadelli-Fiume G, Menotti L, Avitabile E, Gianni T. Viral and cellular contributions to herpes simplex virus entry into the cell. Curr Opin Virol 2012;2(1): 28-36
15. Connolly SA, Jackson JO, Jardetzky TS, Longnecker R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol 2011; 9(5):369-81
16. Karasneh GA, Shukla D. Herpes simplex virus infects most cell types in vitro: clues to its success. Virol J 2011;8:481
17. Conrady CD, Drevets DA, Carr DJJ. Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing? J Neuroimmunol 2010; 220(1-2):1-9
18. Kramer T, Enquist LW. Directional spread of alphaherpesviruses in the nervous system. Viruses 2013;5(2):678-707
19. Kennedy PGE, Cohrs RJ. Varicella-zoster virus human ganglionic latency: a current summary. J Neurovirol 2010;16(6):411-18
20. Wheeler CE. The herpes simplex problem. J Am Acad Dermatol 1988;18(1 Pt 2):163-8
21. Theobald S. Observations upon Herpes Corneae "Febrilis," with Reference, Especially, to Etiology. Trans Am Ophthalmol Soc 1916;14(Pt 2):520-7
22. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296(8):964-73
23. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2-United States, 1999-2010. J Infect Dis 2014;209(3): 325-33
24. Schulte JM, Bellamy AR, Hook EW, et al. HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women). South Med J 2014;107(2):79-84
25. Miller CS, Danaher RJ. Asymptomatic shedding of herpes simplex virus (HSV) in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105(1): 43-50
26. Kaufman HE, Azcuy AM, Varnell ED, et al. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci 2005;46(1):241-7
27. Inoue H, Motani-Saitoh H, Sakurada K, et al. Detection of varicella-zoster virus DNA in 414 human trigeminal ganglia from cadavers by the polymerase chain reaction: a comparison of the detection rate of varicella-zoster virus and herpes simplex virus type 1. J Med Virol 2010;82(2):345-9
28. Motani H, Sakurada K, Ikegaya H, et al. Detection of herpes simplex virus type 1 DNA in bilateral human trigeminal ganglia and optic nerves by polymerase chain reaction. J Med Virol 2006;78(12): 1584-7
29. Liedtke W, Opalka B, Zimmermann CW, Lignitz E. Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. J Neurol Sci 1993;116(1):6-11
30. Hill JM, Ball MJ, Neumann DM, et al. The high prevalence of herpes simplex virus type 1 DNA in human trigeminal ganglia is not a function of age or gender. J Virol 2008;82(16):8230-4
31. Hook EW, Cannon RO, Nahmias AJ, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis 1992;165(2):251-5
32. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy Results of a Trial of a Herpes Simplex Vaccine. N Engl J Med 2012; 366(1):34-43
33. Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013;56(3):344-51
34. Tunbridge AJ, Breuer J, Jeffery KJM; British Infection Society. Chickenpox in adults - clinical management. J Infect 2008; 57(2):95-102
35. American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 2000;105(1 Pt 1): 136-41
36. Uchio E, Hatano H, Mitsui K, et al. A retrospective study of herpes simplex keratitis over the last 30 years. Jpn J Ophthalmol 1994;38(2):196-201
37. Koelle DM, Ghiasi H. Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Curr Eye Res 2005;30(11):929-42
38. Knickelbein JE, Hendricks RL, Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv Ophthalmol 2009;54(2):226-34
39. Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol 2003;121(1): 108-12
40. Liesegang TJ, Melton LJ, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989;107(8):1155-9
41. Chentoufi AA, Benmohamed L. Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections. Clin Dev Immunol 2012;2012:149135
42. Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group. Cornea 2001;20(2):123-8
43. Chong E-M, Wilhelmus KR, Matoba AY, et al. Herpes simplex virus keratitis in children. Am J Ophthalmol 2004;138(3): 474-5
44. Levy J, Lapid-Gortzak R, Klemperer I, Lifshitz T. Herpes simplex virus keratitis after laser in situ keratomileusis. J Refract Surg 1995;21(4):400-2
45. Moshirfar M, Welling JD, Feiz V, et al. Infectious and noninfectious keratitis after laser in situ keratomileusis Occurrence, management, and visual outcomes. J Cataract Refract Surg 2007;33(3):474-83
46. De Rojas Silva V, Rodríguez-Conde R, Cobo-Soriano R, et al. Laser in situ keratomileusis in patients with a history of ocular herpes. J Cataract Refract Surg 2007; 33(11):1855-9
47. Pepose JS, Keadle TL, Morrison LA. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol 2006;141(3):547-57
48. Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi RA, et al. Herpes simplex virus vaccine in recurrent herpetic ocular infection. Cornea 1999;18(1):47-51
49. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-84
50. Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc 2013;88(6):562-70
51. Krall P, Kubal A. Herpes zoster stromal keratitis after varicella vaccine booster in a pediatric patient. Cornea 2014;33(9):988-9
52. Naseri A, Good WV, Cunningham ET. Herpes zoster virus sclerokeratitis and anterior uveitis in a child following varicella vaccination. Am J Ophthalmol 2003;135(3): 415-17
53. Hwang CW, Steigleman WA, Saucedo-Sanchez E, Tuli SS. Reactivation of herpes zoster keratitis in an adult after varicella zoster vaccination. Cornea 2013; 32(4):508-9
54. Gonzales JA, Levison AL, Stewart JM, et al. Retinal necrosis following varicella-zoster vaccination. Arch Ophthalmol 2012; 130(10):1355-6
55. Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK. Acute retinal necrosis after herpes zoster vaccination. Arch Ophthalmol 2011;129(11):1495-7
56. Fine HF, Kim E, Flynn TE, et al. Acute posterior multifocal placoid pigment epitheliopathy following varicella vaccination. Br J Ophthalmol 2010;94(3): 282-3; 363
57. Lin P, Yoon MK, Chiu CS. Herpes zoster keratouveitis and inflammatory ocular hypertension 8 years after varicella vaccination. Ocul Immunol Inflamm 2009; 17(1):33-5
58. Esmaeli-Gutstein B, Winkelman JZ. Uveitis associated with varicella virus vaccine. Am J Ophthalmol 1999;127(6):733-4
59. Ross A, McLean TW, Farber R, et al. Retinitis following varicella in a vaccinated child with acute lymphoblastic leukemia. Pediatr Blood Cancer 2005;45(2):191-4
60. Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis 2013;208(4):559-63
61. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17(7):1055-65
62. Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: seventy-seven cases. Pediatrics 1975;56(3): 388-97
63. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197(6): 825-35
64. Belshe RB, Heineman TC, Bernstein DI, et al. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis 2014;209(6):828-36
65. De Gregorio E, Rappuoli R. From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol 2014; 14(7):505-14
66. Malkevitch NV, Robert-Guroff M. A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines 2004;3(4 Suppl):S105-17
67. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6(2):148-58
68. Nesburn AB, Bettahi I, Zhang X, et al. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul Surf 2006;4(4): 178-87
69. Schumacher AJ, Mohni KN, Kan Y, et al. The HSV-1 exonuclease, UL12, stimulates recombination by a single strand annealing mechanism. PLoS Pathog 2012;8(8): e1002862
70. Wilkinson DE, Weller SK. The role of DNA recombination in herpes simplex virus DNA replication. IUBMB Life 2003;55(8): 451-8
71. Schaffer PA, Tevethia MJ, Benyesh-Melnick M. Recombination between temperature-sensitive mutants of herpes simplex virus type 1. Virology 1974; 58(1):219-28
72. Pan D, Coen DM. Quantification and analysis of thymidine kinase expression from acyclovir-resistant G-string insertion and deletion mutants in herpes simplex virus-infected cells. J Virol 2012;86(8): 4518-26
73. Van Velzen M, van de Vijver DAMC, van Loenen FB, et al. Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. J Infect Dis 2013;208(9): 1359-65
74. Todo T. Active immunotherapy: oncolytic virus therapy using HSV-1. Adv Exp Med Biol 2012;746:178-86
75. Hersey P, Gallagher S. Intralesional immunotherapy for melanoma. J Surg Oncol 2014;109(4):320-6
76. Genetically Engineered HSV-1 Phase 1 Study (M032-HSV-1). Available from: https://clinicaltrials.gov/ct2/show/NCT02062827
77. Nicholas J. Evolutionary aspects of oncogenic herpesviruses. Mol Pathol 2000; 53(5):222-37
78. Steain M, Slobedman B, Abendroth A. Experimental models to study varicella-zoster virus infection of neurons. Curr Top Microbiol Immunol 2010;342: 211-28
79. Dasgupta G, Chentoufi AA, Kalantari M, et al. Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. J Virol 2012;86(8):4358-69
80. Ghiasi H, Perng GC, Nesburn AB, Wechsler SL. Antibody-dependent enhancement of HSV-1 infection by anti-gK sera. Virus Res 2000;68(2):137-44
81. Mott KR, Osorio Y, Maguen E, et al. Role of anti-glycoproteins D (anti-gD) and K (anti-gK) IgGs in pathology of herpes stromal keratitis in humans. Invest Ophthalmol Vis Sci 2007;48(5):2185-93
82. Halford WP, Gebhardt BM, Carr DJ. Acyclovir blocks cytokine gene expression in trigeminal ganglia latently infected with herpes simplex virus type 1. Virology 1997; 238(1):53-63
83. Stuart PM, Keadle TL. Recurrent herpetic stromal keratitis in mice: a model for studying human HSK. Clin Dev Immunol 2012;2012:728480
84. Webre JM, Hill JM, Nolan NM, et al. Rabbit and mouse models of HSV-1 latency, reactivation, and recurrent eye diseases. J Biomed Biotechnol 2012;2012:612316
85. Dasgupta G, BenMohamed L. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates? Vaccine 2011;29(35): 5824-36
86. Kuo T, Wang C, Badakhshan T, et al. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Vaccine 2014; 32(50):6733-45
87. Khodai T, Chappell D, Christy C, et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol 2011;18(10):1702-9
88. Conrady CD, Zheng M, Fitzgerald KA, et al. Resistance to HSV-1 infection in the epithelium resides with the novel innate sensor, IFI-16. Mucosal Immunol 2012; 5(2):173-83
89. Conrady CD, Zheng M, Stone DU, Carr DJJ. CD8+ T cells suppress viral replication in the cornea but contribute to VEGF-C-induced lymphatic vessel genesis. J Immunol 1950;189(1):425-32
90. Wuest T, Zheng M, Efstathiou S, et al. The Herpes Simplex Virus-1 Transactivator Infected Cell Protein-4 Drives VEGF-A Dependent Neovascularization. PLoS Pathog 2011;7(10):e1002278
91. Schrimpf JE, Tu EM, Wang H, et al. B7 costimulation molecules encoded by replication-defective, vhs-deficient HSV-1 improve vaccine-induced protection against corneal disease. PLoS One 2011;6(8): e22772
92. Ma JZ, Russell TA, Spelman T, et al. Lytic gene expression is frequent in HSV-1 latent infection and correlates with the engagement of a cell-intrinsic transcriptional response. PLoS Pathog 2014;10(7): e1004237
93. Knickelbein JE, Khanna KM, Yee MB, et al. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008;322(5899):268-71
94. St Leger AJ, Peters B, Sidney J, et al. Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice. J Immunol 1950;186(7):3927-33
95. Himmelein S, St Leger AJ, Knickelbein JE, et al. Circulating herpes simplex type 1 (HSV-1)-specific CD8+ T cells do not access HSV-1 latently infected trigeminal ganglia. Herpesviridae 2011;2(1):5
96. Krawczyk A, Krauss J, Eis-Hubinger AM, et al. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J Virol 2011;85(4):1793-803
97. Krawczyk A, Arndt MAE, Grosse-Hovest L, et al. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci USA 2013;110(17):6760-5
98. Halford WP, Geltz J, Gershburg E. Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. PLoS One 2013;8(6):e65523
99. Hill JM, Nolan NM, McFerrin HE, et al. HSV-1 latent rabbits shed viral DNA into their saliva. Virol J 2012;9:221
100. Chentoufi AA, Dasgupta G, Christensen ND, et al. A novel HLA (HLA-A∗0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol 1950;184(5):2561-71
101. Nesburn AB, Slanina S, Burke RL, et al. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol 1998;72(10):7715-21
102. Flynn TH, Ohbayashi M, Dawson M, et al. Use of ultrasonic pachymetry for measurement of changes in corneal thickness in mouse corneal transplant rejection. Br J Ophthalmol 2010;94(3):368-71
103. Cortina MS, He J, Russ T, et al. Neuroprotectin D1 restores corneal nerve integrity and function after damage from experimental surgery. Invest Ophthalmol Vis Sci 2013;54(6):4109-16
104. Prusky GT, West PW, Douglas RM. Behavioral assessment of visual acuity in mice and rats. Vision Res 2000;40(16): 2201-9
105. Prusky GT, Alam NM, Beekman S, Douglas RM. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci 2004;45(12):4611-16
106. Wuest TR, Carr DJJ. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. J Exp Med 2010; 207(1):101-15
107. Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection. Available from: https://clinicaltrials.gov/ct2/show/NCT01915212
108. Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-Positive Adults. Available from: https://clinicaltrials.gov/ct2/show/NCT00698893
109. HerpeVac Trial for Young Women. Available from: https://clinicaltrials.gov/ct2/show/NCT00057330
110. Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults. Available from: https://clinicaltrials.gov/ct2/show/NCT02030301
111. Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines. Available from: https://clinicaltrials.gov/ct2/show/NCT00698490
112. Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2. Available from: https://clinicaltrials.gov/ct2/show/NCT00274300
113. Herpevac Neonatal Substudy. Available from: https://clinicaltrials.gov/ct2/show/NCT00138320
114. Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive/Seronegative Subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT00698568
115. Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine. Available from: https://clinicaltrials.gov/ct2/show/NCT02114060
116. Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Subjects With Recurrent Genital Herpes. Available from: https://clinicaltrials.gov/ct2/show/NCT01687595
117. Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine. Available from: https://clinicaltrials.gov/ct2/show/NCT01667341
118. Trial Evaluating Safety, Tolerability and Immune Response of AG-707. Available from: https://clinicaltrials.gov/ct2/show/NCT00231049
119. Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT00699764
120. Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant. Available from: https://clinicaltrials.gov/ct2/show/NCT00697567
121. Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine. Available from: https://clinicaltrials. gov/ct2/show/NCT00224471
122. Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old. Available from: https://clinicaltrials.gov/ct2/show/NCT00224484